Navigation Links
Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD
Date:10/29/2008

Data also found SYMBICORT opened airways in less than 15 minutes

WILMINGTON, Del., Oct. 29 /PRNewswire-FirstCall/ -- Data presented today from two pivotal efficacy and safety trials, SHINE and SUN, demonstrated that SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol significantly improved lung function and was well-tolerated in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) relative to budesonide and formotorol administered alone, and placebo.(1,2,3,4) Both trials showed safety profiles consistent with the established profiles in asthma for each product.(2,4) In addition, an analysis of these trials showed that patients receiving SYMBICORT achieved a bronchodilatory effect, or opening of the airways, similar to formoterol DPI, and a more rapid effect than that achieved by either budesonide pMDI or placebo.(5) Results were presented today at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians, held in Philadelphia, October 25-30, 2008.

In April 2008, AstraZeneca submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SYMBICORT for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. SYMBICORT is a combination therapy currently indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older.(6) SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.(6)

"Results of the SHINE and SUN trials demonstrated that SYMBICORT improved lung function and was well-tolerated by study patients with COPD,(1,2,3,4) and if approved by the FDA, it could offer a new treatment option for the millions of Americans suffering from this debilitating disease," said lead investigator Donald Tashkin, M.D., of the University of California, Los Angeles (U
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
4. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
5. Recruitment Completed in Ofatumumab NHL Pivotal Study
6. Pivotal National Trial Uses Newest Interventional Radiology Treatment to Bust Blood Clots in Legs
7. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
8. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
9. 338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment
10. Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
11. First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... SAINT PAUL, Minn. , Aug. 1, 2014 ... leading global medical technologies company, announced today that ... a privately held manufacturer of cardiorespiratory diagnostic products ... MediSoft has served the European cardiorespiratory ... company, generated 2013 revenues of approximately €4.7 million ...
(Date:8/1/2014)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... study evaluating ISIS-SMN Rx in infants with spinal ... infant mortality. Isis plans to dose the first infant ... which time Isis will earn an $18 million milestone ... 3 study, ENDEAR, is the first of several planned ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... (PRWEB) August 01, 2014 Growing ... coverage and healthcare reforms are boosting healthcare market ... medicines through discounts and increasing generic consumption is ... approximately 76.7 million in 2013, having grown at ... from 2008. The implementation of the Health Transformation ...
(Date:8/1/2014)... Hawley, PA (PRWEB) August 01, 2014 Hot ... in the destination spa category of the World’s Best ... kicks off a month-long celebration of National Relaxation Day (technically ... together a series of MAJOR experts to help guests celebrate ... how important it is for health and wellness to carve ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by ... Oxide, Titanium Dioxide, and Zinc Omadine), Application (Indoor ... & Beverages, Textiles, and others), & Geography (North ... and Forecasts to 2018" analyzes the Antimicrobial Coatings ... trends in the diverse geographical regions. , Browse ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. ... as a time-honored destination for a good cut and conversation. ... also be the spot to tackle an often overlooked health ... novel partnership, the U.S. Centers for Disease Control and Prevention, ... the help of barbershop staff to both discuss and diagnose ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
Breaking Medicine News(10 mins):Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4
... Inc. (AIS), publisher of industry-leading newsletters Health Plan,Week, ... pleased to announce,publication of "Managed Medicare and Medicaid ... and almost 30 million Medicaid recipients,enrolled in managed ... other,companies with a stake in this market place ...
... 21 Mylan Inc. (NYSE: MYL ),today ... approval,from the U.S. Food and Drug Administration (FDA) ... Extended-release Tablets USP, 2.5,mg, 5 mg and 10 ... generic version of,AstraZeneca Pharmaceutical,s Plendil(R) Extended-release tablets, which ...
... upcoming Public Meeting on April 22, 2008, the Centers ... input for the establishment of a Healthcare Common Procedure ... II of the HCPCS is a standardized coding system ... not included in the Current Procedural Terminology (CPT) coding ...
... -- China Medicine,Corporation (OTC Bulletin Board: CHME; ... and developer of ethical and over-the-counter drugs,traditional ... devices, and medical formulations in the PRC, ... the Guangzhou Technology Bureau to represent,Guangzhou city,s ...
... Research Group survey finds that approximately 45% of physicians, intend to ... ... years, WALTHAM, Mass., April ... at the American Academy of,Orthopedic Surgeons, annual meeting in San Francisco, CA, ...
... BRIGHTON, England, April 21 Futuremedia,Learning, a leading ... Bulletin Board: FMDAY), has launched Performance Zone, a ... health,and care organisation., The launch took place ... the,UK, with Futuremedia Learning staff on-site offering support ...
Cached Medicine News:Health News:New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits 2Health News:Medicare to consider public opinion about medical maggots 2Health News:Medicare to consider public opinion about medical maggots 3Health News:China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention 2Health News:China Medicine Corporation Selected to Represent Biotechnology Industry of Guangzhou City at 2008 Annual BIO International Convention 3Health News:Physicians Anticipate Changes in Their Usage of Hip Implants 2Health News:Futuremedia Learning Launches Next Generation Learning Portal for Bupa 2
... collect sample, pipette into testing wells ... FDA 510K cleared multiple drug screen ... both drugs and adulterants. It can ... (5) drugs and can be accompanied ...
... Glucose Monitoring System is a patient insertable short-term ... the DexCom STS Receiver., The DexCom STS Sensor ... the DexCom STS Applicator by the user or ... held in place by an adhesive to the ...
... routine Holter,monitoring, the Burdick Vision ... a,practical, no-nonsense diagnostic tool ideal,for ... This highly accurate and,easy-to-use system ... configurations at a price even ...
... PC-based ECG diagnostics complements transition to ... the incorporation of computer-based technology into ... diagnostic instrumentation have developed. Burdick's Universal ... EMRs making it the ideal choice ...
Medicine Products: